Publikationsdatum:
2011-07-09
Beschreibung:
〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Couzin-Frankel, Jennifer -- Ogale, Yasmin -- New York, N.Y. -- Science. 2011 Jul 8;333(6039):143-4. doi: 10.1126/science.333.6039.143.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/21737712" target="_blank"〉PubMed〈/a〉
Schlagwort(e):
Angiogenesis Inhibitors/adverse effects/economics/*therapeutic use
;
Antibodies, Monoclonal/adverse effects/economics/*therapeutic use
;
Antibodies, Monoclonal, Humanized
;
Bevacizumab
;
Breast Neoplasms/*drug therapy/mortality
;
*Drug Approval
;
Drug Costs
;
Female
;
Humans
;
Survival Rate
;
United States
;
*United States Food and Drug Administration
Print ISSN:
0036-8075
Digitale ISSN:
1095-9203
Thema:
Biologie
,
Chemie und Pharmazie
,
Informatik
,
Medizin
,
Allgemeine Naturwissenschaft
,
Physik
Permalink